CD19 and Miyoshi myopathy: In contrast, non-hemodiluted BM samples from treated MM patients (i.e., end of induction and day+100 after ASCT) showed an overall increased frequency of stage I and stage II BCP (p ≤ 0.001) vs. age-matched normal BM and vs. MM BM obtained at diagnosis (0.1% vs. 0.02% and 0.0005%, and 1.1% vs. 0.3% and 0.01%, respectively), while memory B-cell (0.04% vs. 0.4%) and nPC (0.06% vs. 0.2% and 0.007% vs. 0.1% for CD19+ and CD19− nPC, respectively) subsets were both significantly (p ≤ 0.001) decreased vs. normal BM (Table 1 and Figure 1).